Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) Shares Outstanding (Weighted Average) (2016 - 2025)

Anaptysbio filings provide 10 years of Shares Outstanding (Weighted Average) readings, the most recent being $28.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.32% year-over-year to $28.8 million, compared with a TTM value of $28.8 million through Dec 2025, up 1.32%, and an annual FY2025 reading of $28.8 million, up 1.32% over the prior year.
  • Shares Outstanding (Weighted Average) hit $28.8 million in Q4 2025 for Anaptysbio, down from $29.1 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $30.6 million in Q1 2025, with the low at $26.5 million in Q3 2023.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $27.8 million (2022), compared with a mean of $28.0 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) dropped 6.16% in 2023, then rose 14.34% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $27.4 million in 2021, then increased by 2.68% to $28.2 million in 2022, then dropped by 4.41% to $26.9 million in 2023, then increased by 5.42% to $28.4 million in 2024, then rose by 1.32% to $28.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $28.8 million, $29.1 million, and $29.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.